ReviewJournal of andrology
Modeling prostate cancer in mice: limitations and opportunities.
Review in Journal of andrology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Modeling human prostate cancer progression in vitro.Carcinogenesis · 2019Pooled it
- Neuromedin U 'innervation' reprograms myeloid immunosuppression in neuroendocrine prostate cancer.Oncogene · 2026Article
- Formation of tertiary lymphoid structures drives Parkin antitumor immunity.Science advances · 2026Article
- Differential Effects of a First-in-Class IKKCalcified tissue international · 2026Article
- Reproducible preclinical models of androgen receptor driven human prostate cancer bone metastasis.The Prostate · 2024Article
- Orexins and Prostate Cancer: State of the Art and Potential Experimental and Therapeutic Perspectives.Cancer genomics & proteomics · 2023Review
- Tomatoes, Lycopene, and Prostate Cancer: What Have We Learned from Experimental Models?The Journal of nutrition · 2022Review
- Comparative Pathobiology of Canine and Human Prostate Cancer: State of the Art and Future Directions.Cancers · 2022Review
- Dimethylaminomicheliolide Sensitizes Cancer Cells to Radiotherapy for Synergistic Combination with Immune Checkpoint Blockade.Advanced therapeutics · 2022Article
- Proteomic discovery of non-invasive biomarkers of localized prostate cancer using mass spectrometry.Nature reviews. Urology · 2021Review
- Cellular senescence as a possible link between prostate diseases of the ageing male.Nature reviews. Urology · 2021Review
- Recent Developments and Applications of Quantitative Proteomics Strategies for High-Throughput Biomolecular Analyses in Cancer Research.RSC chemical biology · 2021Article
- Epithelial protein lost in neoplasm (EPLIN) and prostate cancer: lessons learned from the ARCaP model.American journal of clinical and experimental urology · 2021Review
- Alzheimer's Disease, and Breast and Prostate Cancer Research: Translational Failures and the Importance to Monitor Outputs and Impact of Funded Research.Animals : an open access journal from MDPI · 2020Review
- A QSP model of prostate cancer immunotherapy to identify effective combination therapies.Scientific reports · 2020Article
- Development of Zinc-Specific iCEST MRI as an Imaging Biomarker for Prostate Cancer.Angewandte Chemie (International ed. in English) · 2019Article
- Genetics and biology of prostate cancer.Genes & development · 2018Review
- Characterization of the effects of defined, multidimensional culture conditions on conditionally reprogrammed primary human prostate cells.Oncotarget · 2018Article
- Prediction of treatment efficacy for prostate cancer using a mathematical model.Scientific reports · 2016Article
- Animal Models of Bone Metastasis.Veterinary pathology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The complex dynamics of the tumor microenvironment and prostate cancer heterogeneity have confounded efforts to establish suitable preclinical mouse models to represent human cancer progression from early proliferative phenotypes to aggressive, androgen-independent, and invasive metastatic tumors. Current models have been successful in capitulating individual characteristics of the aggressive tumors. However, none of these models comprehensively mimics human cancer progression, establishing the challenge in their exploitation to study human disease. The ability to tailor phenotypic outcomes in mice by compounding mutations to target specific molecular pathways provides a powerful tool toward disruption of signaling pathways contributing to the initiation and progression of castration-resistant prostate cancer. Each model is characterized by unique features contributing to the understanding of prostate tumorigenesis, as well as limitations challenging our knowledge of the mechanisms of cancer development and progression. Emerging strategies utilize genomic manipulation technology to circumvent these limitations toward the formulation of attractive, physiologically relevant models of prostate cancer progression to advanced disease. This review discusses the current value of the widely used and well-characterized mouse models of prostate cancer progression to metastasis, as well as the opportunities begging exploitation for the development of new models for testing the antitumor efficacy of therapeutic strategies and identifying new biomarkers of disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.